We are reinventing the fundamental science underlying the development of new medicines and their use in individual patients.
The Laboratory of Systems Pharmacology (LSP) uses a team science approach to advance the fundamental science and technology needed to develop new medicines and personalized patient care.
We study the molecular causes of disease, how drugs exert their therapeutic and adverse effects, how clinical trials are designed and interpreted, and how machine learning and AI can help identify new molecular targets in diseases like cancer, Alzheimer’s, tuberculosis, and chronic pain.
The LSP is a research and education program that is part of the Harvard Program in Therapeutic Science (HiTS). Our organization prepares students and fellows for leadership roles in academic research, industry, and government service.
Explore LSP Research
News, Events, & Updates
LSP Social Lunch
“Laboratory of Sustainable Practices”
Wednesday, June 26 | 11:30am-1:00pm
Countway Community Garden
LSP Articles Selected for ‘Best of Cell 2023’ and ‘Nature Cancer’s 2023 in Review’
‘Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer,’
was selected as the Best of Cell 2023. This project led to the development of one of the first 3D human tissue atlases.
was highlighted in Nature Cancer’s 2023 in Review.
Twitter @HiTSatHarvard
Alex's research has allowed us to peer into tumors in a way that we never thought was possible - his talk will surely be stunning! 🔬💫
Team Pathology is walking Now in the @TheJimmyFund Walk!! Donate now to help fund cancer research!
3
Join us on Monday @harvardmed at 3PM for two fantastic discussions focusing on cell death in radiation therapy and breast cancer metastasis!
📢 Our October 2024 #ResearchDataManagement Newsletter is out!
🍎 @lmardmwg Fall RDM Training
🦖 Research Data Thesaurus
📋 RDM Lifecycle Checklist
🔓 @harvardlibrary Open Access Week 2024
🤣 Just for Fun @ErrantScience
Read the whole issue now ➡️ https://mailchi.mp/harvard/rdm-newsletter-oct-2024-vol-7-iss-4
Multi-institutional effort for the precancer atlas of high grade serous ovarian carcinoma (HGSOC). We have discovered gradual changes in the precancer microenvironment by multimodal spatial profiling, a shift from immune surveillance to immune suppression.